In a nutshell This article reviewed the effectiveness and safety of neratinib (Nerlynx) in patients with human epidermal receptor growth factor 2+ (HER2+) breast cancer. This article concluded that neratinib is effective in treating patients with HER2+ breast cancer, with manageable side effects. Some background Between 15 and 20%...
Read More
In a nutshell This study determined whether using vitamin D and E suppositories improved symptoms of vaginal atrophy in women with breast cancer treated with tamoxifen (Nolvadex). The study found that using vitamin D and E suppositories decreased feelings of vaginal dryness and pain for these patients. Some background Vaginal...
Read MoreIn a nutshell This study examined the effects of neratinib (Nerlynx) in women with early-stage breast cancer. This study found that treatment with neratinib decreased the quality of life of these patients during the first month of treatment due to side effects. Some background Between 15 and 20% of patients diagnosed with...
Read MoreIn a nutshell This trial aims to find out how well a new drug (DS-8201a) works on breast cancer that expresses low levels of the HER2 receptor and is not able to be operated on. The main outcome that will be measured is survival without cancer growing or spreading. The details The drug DS-8201a is a new anti-cancer drug that works against breast...
Read More
In a nutshell This study determined whether treating breast cancer that has spread (metastatic) with olaparib (Lynparza) resulted in better outcomes and fewer side effects compared to chemotherapy. The study found that treatment with olaparib led to similar survival outcomes compared to chemotherapy. Some background There are...
Read More
In a nutshell This study determined whether treating breast cancer that has spread (metastatic) with olaparib (Lynparza) resulted in better outcomes and fewer side effects compared to chemotherapy. The study found that treatment with olaparib led to similar survival outcomes compared to chemotherapy. Some background There are...
Read More
In a nutshell This study wanted to find out which of three medicines was best for treating breast cancer, palbociclib (Ibrance), ribociclib (Kisquali), or abemaciclib (Verzenio). The study found that the medications all worked equally as well, but there were different side effects for each one. Some background Estrogen receptor positive (ER+) breast...
Read MoreIn a nutshell This trial aims to investigate a new cancer medicine called xentuzumab together with exemestane (Aromasin) and everolimus (Afinitor) in women who have breast cancer that has spread. The main outcome that will be measured is how long the patients go without cancer growing. The details Xentuzumab is a new medication that works...
Read More
In a nutshell This article investigated the long-term safety and effectiveness of autologous breast reconstruction (ABR; uses tissue from another place on your body to form a breast shape) on women after breast removal for invasive breast cancer. The authors concluded that this treatment is safe and had no effect on relapse...
Read MoreIn a nutshell This trial aims to see if combining two medications, T-DM1 (Kadcycla) and palbociclib (Ibrance) is better than just using T-DM1 in treating HER2+ breast cancer that has spread. The main outcome that will be measured is survival without the cancer growing or spreading. The study is being conducted in Arizona, the United States. The...
Read More
In a nutshell This study wanted to find out if the risk of patients with breast cancer developing a blood clot was higher if they were treated with aromatase inhibitors, or tamoxifen (Nolvadex). The study found that the patients treated with tamoxifen had a higher risk of developing blood clots compared to those treated with aromatase...
Read More
In 1904, a physician wrote about a patient with leukemia who went into remission when he got the flu. Though the patient was not cured, it was a ray of hope at a time when there were no treatments for leukemia. Other cases were reported throughout the years of people with Burkitt’s Lymphoma and Hodgkin’s Lymphoma going into remission when they...
Read More
